Premium
Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors
Author(s) -
Gutin Philip H.,
Wilson Charles B.,
Kumar A. R. Vansantha,
Boldrey Edwin B.,
Levin Victor,
Powell Malcolm,
Enot K. J.
Publication year - 1975
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197505)35:5<1398::aid-cncr2820350524>3.0.co;2-c
Subject(s) - procarbazine , medicine , vincristine , chemotherapy , lomustine , radiation therapy , combination chemotherapy , oncology , cyclophosphamide
Forty‐eight patients with primary or metastatic malignant tumors of the central nervous system (CNS) were treated with combination chemotherapy, consisting of procarbazine (100 mg/m 2 × 14 days), CCNU (75 mg/m 2 ), and vincristine (1.4 mg/m 2 × 2, 1 week apart) (PCV) every 4 weeks. Most patients had undergone initial resection of primary tumors, postoperative radiotherapy, and a post irradiation interval of 3 months or more. Other patients harbored unbiopsied, newly‐discovered primary or metastatic tumors. All patients were deteriorating neurologically when treatment began. Overall response rate for PCV combination therapy was 44%, no better than results obtained with single agent procarbazine or BCNU, the most effective drugs used alone in previous brain tumor chemotherapy studies.